NCT00534469View on ClinicalTrials.gov

Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 8, 2000

Primary Completion Date

December 31, 2022

Study Completion Date

August 22, 2025

Conditions
Leukemia
Interventions
BIOLOGICAL

aldesleukin

BIOLOGICAL

filgrastim

DRUG

busulfan

DRUG

cytarabine

DRUG

etoposide

DRUG

idarubicin

PROCEDURE

autologous hematopoietic stem cell transplantation

PROCEDURE

bone marrow transplantation

PROCEDURE

peripheral blood stem cell transplantation

RADIATION

total-body irradiation

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER